Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study
2018/03/24 by Mark James Rawle, Rachel Cooper, Diana Kuh +1 · 29 citations
Medicine · #Pharmaceutical Practices and Patient Outcomes #Dementia and Cognitive Impairment Research #Intensive Care Unit Cognitive Disorders
paper · pdf · doi:10.1111/jgs.15317
Abstract
OBJECTIVES: To investigate longitudinal associations between polypharmacy and cognitive and physical capability and to determine whether these associations differ with cumulative exposure to polypharmacy. DESIGN: Prospective birth cohort study. SETTING: England, Scotland, and Wales. PARTICIPANTS: An eligible sample of men and women from the Medical Research Council National Survey of Health and Development with medication data at age 69 (N=2,122, 79%). MEASUREMENTS: Cognitive capability was assessed using a word learning test, visual search speed task, and the Addenbrooke's Cognitive Examination, Third Edition (ACE-III). Physical capability was measured using chair rise speed, standing balance time, walking speed, and grip strength. RESULTS: Polypharmacy (5-8 prescribed medications) was present in 18.2% of participants at age 69 and excessive polypharmacy (≥9 prescribed medications) in 4.7%. Both were associated with poorer cognitive and physical capability in models adjusted for sex, education, and disease burden. Stronger associations were found for excessive polypharmacy (e.g., difference in mean ACE-III scores comparing polypharmacy=-2.0, 95% CI=-2.8 to -1.1 and excessive polypharmacy=-2.9, 95% CI=-4.4 to -1.4 with no polypharmacy). Participants with polypharmacy at age 60 to 64 and at age 69 showed stronger Negative associations with cognitive and physical capability were stronger still in participants with polypharmacy at both age 60 to 64 and at age 69 (e.g. difference in mean chair rise speed, comparing polypharmacy with no polypharmacy at both ages=-3.9, 95% CI=-5.2 to -2.6 and at age 60-64 only=-2.5, 95% CI=-4.1 to -0.9). CONCLUSION: Polypharmacy at age 60 to 64 and age 69 was associated with poorer physical and cognitive capability, even after adjusting for disease burden. Stronger negative associations were seen in participants with longstanding polypharmacy, suggesting a cumulative, dose-dependent relationship (where dose is the number of prescribed medications). Future research aiming to improve cognitive and physical capability should consider interventions to reduce the duration and level of polypharmacy at younger ages, in addition to optimizing disease control with appropriate medications.
Cited by
- Deprescribing considerations for central nervous system‐active polypharmacy in patients with dementia
- Polypharmacy: A general review of definitions, descriptions and determinants
- Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR)
- Factors negatively affecting quality of life in geriatric patients: review
- The association between polypharmacy and late life deficits in cognitive, physical and emotional capability: a cohort study. [europepmc]
- Identifying the lifetime cognitive and socioeconomic antecedents of cognitive state: seven decades of follow-up in a British birth cohort study. [europepmc]
- A Comprehensive Overview of Polypharmacy in Elderly Patients in Saudi Arabia. [europepmc]
- The Association Between Polypharmacy and Physical Function in Older Adults: a Systematic Review. [europepmc]
- Polypharmacy and injurious falls in older adults: a nationwide nested case-control study. [europepmc]
- Factors associated with medication adherence in older patients: A systematic review. [europepmc]
- Physical multimorbidity and subjective cognitive complaints among adults in the United Kingdom: a cross-sectional community-based study. [europepmc]
- Prevalence, Determinants And Associated Risk Of Potentially Inappropriate Prescribing For Older Adults In Qatar: A National Retrospective Study. [europepmc]
- The challenge of HIV treatment in an era of polypharmacy. [europepmc]
- Psychotropic Polypharmacy in Adults 55 Years or Older: A Risk for Impaired Global Cognition, Executive Function, and Mobility. [europepmc]
- Chronic polypharmacy impairs explorative behavior and reduces synaptic functions in young adult mice. [europepmc]
- Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study. [europepmc]
- Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. [europepmc]
- Polypharmacy and Malnutrition Management of Elderly Perioperative Patients with Cancer: A Systematic Review. [europepmc]
- Two separate, large cohorts reveal potential modifiers of age-associated variation in visual reaction time performance. [europepmc]
- The clinical impact of adherence to therapy in airways disease. [europepmc]
- Older Adults with Hypertension: Prevalence of Falls and Their Associated Factors. [europepmc]
- Persistent polypharmacy and fall injury risk: the Health, Aging and Body Composition Study. [europepmc]
- The Prevalence of Polypharmacy and Potentially Inappropriate Medications and Its Relationship with Cognitive Status in Portuguese Institutionalized Older Adults: A Cross-Sectional Study. [europepmc]
- Relationship of Self Efficacy in Medication Understanding with Quality of Life among Elderly with Type 2 Diabetes Mellitus on Polypharmacy in Malaysia. [europepmc]
- Degree of Polypharmacy and Cognitive Function in Older Women with HIV. [europepmc]
- Polypharmacy and cumulative anticholinergic burden in older adults hospitalized with fall. [europepmc]
- Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes: a snapshot from a community-dwelling sample of older men and women in northern Italy. [europepmc]
- Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review. [europepmc]
- Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR). [europepmc]
Related